drugset / Trial / NCT00645229

A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT00645229

Phase 3 Terminated 1 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms

Timeline

Start
2004-09
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 80 mg